Treatments for migraine and related disorders

Abstract

Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches.

1 .- 46 . (canceled) 
     
     
         47 . A method for treating a patient subject to seizures comprising administering to the patient an effective amount of a composition comprising interleukin-11 (IL-11), wherein treating excludes administering a cytokine to the patient. 
     
     
         48 . The method of  claim 47 , wherein the composition is administered intranasally. 
     
     
         49 . The method of  claim 47 , wherein the composition is administered multiple times. 
     
     
         50 . The method of  claim 47 , wherein the composition is administered on multiple days. 
     
     
         51 . The method of  claim 47 , wherein the composition is administered on multiple consecutive days. 
     
     
         52 . The method of  claim 47 , wherein the patient is suffering from a seizure when the composition is administered. 
     
     
         53 . The method of  claim 47 , wherein the patient is not suffering from a seizure when the composition is administered. 
     
     
         54 . The method of  claim 47 , wherein the patient is administered the composition once a day. 
     
     
         55 . The method of  claim 47 , wherein the composition is administered to the patient's brain cells. 
     
     
         56 . The method of  claim 47 , wherein the composition comprises between about 0.1 ng and about 2.0 g of IL-11. 
     
     
         57 . A method for reducing spreading depression (SD) susceptibility in a patient in need thereof comprising administering to the patient an effective amount of a composition comprising IL-11, wherein reducing SD susceptibility excludes administering a cytokine to the patient. 
     
     
         58 . The method of  claim 57 , wherein the composition is administered intranasally. 
     
     
         59 . The method of  claim 57 , wherein the composition is administered multiple times. 
     
     
         60 . The method of  claim 57 , wherein the composition is administered on multiple days. 
     
     
         61 . The method of  claim 57 , wherein the patient needs protection from demyelination. 
     
     
         62 . The method of  claim 57 , wherein the patient has a demyelinating disease. 
     
     
         63 . The method of  claim 57 , wherein the patient is administered the composition once a day. 
     
     
         64 . The method of  claim 57 , wherein the composition is administered to the patient's brain cells. 
     
     
         65 . The method of  claim 57 , wherein the composition comprises between about 0.1 ng and about 2.0 g of IL-11. 
     
     
         66 . A method for reducing spreading depression (SD) susceptibility in a patient having a demyelinating disease comprising intranasally administering multiple times on multiple days to the patient a composition comprising interleukin-11 (IL-11), wherein reducing spreading depression excludes administering a cytokine to the patient.